8787668 Canada

Akcea Therapeutics Canada is the Canadian subsidiary of Akcea Therapeutics, a biopharmaceutical company focused on developing and commercializing medicines for serious and rare diseases. The company specializes in RNA-targeted therapeutics, particularly antisense oligonucleotides, to treat cardiometabolic and rare diseases. Its lead commercial product in Canada is Tegsedi (inotersen), which is indicated for the treatment of polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). Akcea was established to manage the clinical development and commercialization of Ionis Pharmaceuticals' late-stage pipeline in Canada and other global markets. In 2020, Akcea was fully acquired by its parent company, Ionis Pharmaceuticals, and now operates as a wholly-owned subsidiary.